Clinical Trial Update: TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TQB2450 plus anlotinib hydrochloride as neoadjuvant therapy in resectable hepatocellular carcinoma at high risk of recurrence/metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi | Phase 1, Phase 2 | Status: UNKNOWN